ⓘ LOXL2

                                     

ⓘ LOXL2

This gene encodes a member of the lysyl oxidase gene family. The prototypic member of the family is essential to the biogenesis of connective tissue, encoding an extracellular copper-dependent amine oxidase that catalyses the first step in the formation of crosslinks in collagens and elastin. A highly conserved amino acid sequence at the C-terminus end appears to be sufficient for amine oxidase activity, suggesting that each family member may retain this function. The N-terminus is poorly conserved and may impart additional roles in developmental regulation, senescence, tumor suppression, cell growth control, and chemotaxis to each member of the family.

LOXL2 may also cross-linking of type IV collagen and thus affect the sprouting of new blood vessels.

                                     
  • arthropathy joint pathology and vitreoretinopathy pathology of the eye LOXL 1 LOXL2 LOXL 4 GRCh38: Ensembl release 89: ENSG00000115318 - Ensembl, May 2017 GRCm38:
  • happens in the eye, exfoliation glaucoma results. LOXL 1 has been shown to interact with FBLN5. LOXL2 LOXL 3 LOXL 4 GRCh38: Ensembl release 89: ENSG00000129038
  • cell growth control, and chemotaxis to each member of the family. LOXL 1 LOXL2 LOXL 3 GRCh38: Ensembl release 89: ENSG00000138131 - Ensembl, May 2017 GRCm38:
  • treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator. In January 2016, Gilead Sciences terminated its Phase 2 clinical study in patients with
  • matrix, including neurodegenerative and cardiovascular diseases. LOXL 1 LOXL2 LOXL 3 LOXL 4 Menkes disease Occipital horn syndrome GRCh38: Ensembl release
  • has associated PEX with polymorphisms in gene LOXL 1. A report suggested that a specific gene named LOXL 1 which was a member of the family of enzymes which
  • effects. Simtuzumab is a monoclonal antibody against the pro - fibrotic enzyme LOXL2 that is being developed as a possible therapy for PSC. Chris Klug professional
  • vascular development and remodeling. FBLN5 has been shown to interact with LOXL 1 and apolipoprotein a FBLN5 mutations have been described in patients with
  • 8827 LOXHD1 HGNC: 26521 Q8IVV 2 8828 LOXL 1 HGNC: 6665 Q08397 8829 LOXL2 HGNC: 6666 Q9Y4K0 8830 LOXL 3 HGNC: 13869 P58215 8831 LOXL 4 HGNC: 17171 Q96JB6 8832 LPA